C
Chemomab Therapeutics Ltd.
CMMBCIK 0001534248NasdaqNon-AcceleratedPharmaceutical PreparationsL3ILFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-8.99M
Total Assets
$13.81M
Equity
$12.33M
Shares Out
575.38M
Op. Cash Flow
$-11.10M
Business
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing therapeutics that target inflammation and fibrosis. Its main product candidate is nebokitug, a first-in-class humanized monoclonal antibody designed to bind and neutralize the chemokine CCL24 to provide dual anti‑fibrotic and anti‑inflammatory activity. Key business activities include preclinical research, clinical development programs (notably Phase 2/Phase 3 planning in primary sclerosing cholangitis and a Phase 2‑ready program in systemic sclerosis), intellectual property management and outsourced manufacturing. The company conducts global clinical trials and academic collaborations and plans to commercialize its products either alone or via partnerships, distribution or licensing arrangements across major markets including the United States, European Union and Japan.
Summary from filing dated 2025-04-04
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 | FY 2018 2018-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 17 | 6 | 5 | 13 | 8 | |
| General and administrative | 12 | 6 | 1 | 6 | 6 | |
| Total operating expenses | 29 | 12 | 6 | 23 | 13 | |
| Financing (income) expenses, net | −353,000 | 111,000 | — | — | — | |
| Loss before taxes | 28 | 12 | — | 27 | 13 | |
| Taxes on income (benefit) | −534,000 | 0 | — | — | 306,000 | |
| Net loss for the year | 28 | 12 | 6 | 27 | −14 | |
| Basic loss per Ordinary Share | 0.12 | 0.06 | — | — | — | |
| Diluted loss per Ordinary Share | 0.12 | 0.06 | — | — | — | |
| Weighted average number of Ordinary Shares outstanding, basic | 228 | 207 | — | — | — | |
| Weighted average number of Ordinary Shares outstanding, diluted | 228 | 207 | — | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 | FY 2018 2018-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 14 | 15 | 12 | 18 | 8 | |
| Short-term bank deposit | 26 | 46 | 24,000 | — | — | |
| Restricted cash | 77,000 | 0 | — | — | — | |
| Other receivables and prepaid expenses | 2 | 2 | 141,000 | 636,000 | — | |
| Total current assets | 42 | 63 | 12 | 18 | 11 | |
| Restricted cash | 0 | 55,000 | 53,000 | — | — | |
| Long-term prepaid expenses | 733,000 | 908,000 | — | 57,000 | 1 | |
| Property and equipment, net | 367,000 | 357,000 | 152,000 | 158,000 | 385,000 | |
| Operating lease right-of-use assets | 227,000 | 345,000 | 428,000 | 1 | 2 | |
| Total non-current assets | 1 | 2 | 637,000 | 2 | 2 | |
| Total assets | 43 | 64 | 12 | 20 | 13 | |
| Trade payables | 2 | 1 | 93,000 | 875,000 | 396,000 | |
| Accrued expenses | 3 | 555,000 | 715,000 | — | — | |
| Employee and related expenses | 2 | 653,000 | 438,000 | — | — | |
| Operating lease liabilities | 123,000 | 106,000 | 70,000 | 391,000 | 2 | |
| Total current liabilities | 7 | 3 | 1 | 4 | 3 | |
| Non-current operating lease liabilities | 91,000 | 237,000 | 358,000 | 725,000 | — | |
| Total non-current liabilities | 91,000 | 237,000 | 358,000 | 725,000 | 210,000 | |
| Commitments and contingent liabilities | — | — | — | — | — | |
| Total liabilities | 7 | 3 | 2 | 5 | 3 | |
| Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021 | 0 | 0 | — | — | — | |
| Treasury share at cost (11,640,460 shares as of December 31, 2022) | −1 | 0 | — | — | — | |
| Additional paid-in capital | 101 | 98 | 34 | 119 | 87 | |
| Accumulated deficit | −64 | −36 | −24 | −105 | −78 | |
| Total shareholders' equity | 36 | 61 | 11 | 12 | 10 | |
| Total liabilities and shareholders' equity | 43 | 64 | 12 | 20 | 13 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 | FY 2020 2020-12-31 | FY 2019 2019-12-31 | FY 2018 2018-12-31 |
|---|---|---|---|---|---|---|
| Net loss for the year | −28 | −12 | −6 | −27 | −14 | |
| Depreciation | 58,000 | 34,000 | 24,000 | 281,000 | 66,000 | |
| Share-based compensation | 3 | 2 | 130,000 | 1 | 2 | |
| Change in other receivables and prepaid expenses | −64,000 | −2 | −99,000 | 2 | — | |
| Change in trade payables | 352,000 | 1 | 68,000 | 1 | 287,000 | |
| Change in accrued expenses | 3 | −1 | 392,000 | — | — | |
| Change in employees and related expenses | 907,000 | 215,000 | 194,000 | −347,000 | 528,000 | |
| Change in operating leases | −11,000 | −2,000 | — | — | — | |
| Net cash used in operating activities | −20 | −12 | −5 | −16 | −14 | |
| Investment in deposits | 20 | −46 | −24,000 | — | — | |
| Long-term lease deposit | 0 | 4,000 | — | — | — | |
| Sale of asset held for sale | 0 | 1 | — | — | — | |
| Purchase of property and equipment | −68,000 | −239,000 | −38,000 | −95,000 | 213,000 | |
| Net cash provided by (used in) investing activities | 20 | −45 | −62,000 | −95,000 | −213,000 | |
| Cash acquired in Merger | 0 | 2 | — | — | — | |
| Exercise of options | 143,000 | 10,000 | — | — | — | |
| Treasury share at cost | −1 | 0 | — | — | — | |
| Issuance of shares and warrants, net of issuance costs | 267,000 | 59 | 4 | — | — | |
| Net cash provided by (used in) financing activities | −808,000 | 61 | 5 | 27 | 21 | |
| Change in cash, cash equivalents and restricted cash | −2 | 4 | −554,000 | 10 | 6 | |
| Income taxes received | 351,000 | 0 | — | — | — | |
| Income taxes paid | −5,000 | 0 | 84,000 | 161,000 | 244,000 | |
| Interest received | 972,000 | 74,000 | — | — | — | |
| Right-of-use asset recognized with corresponding lease liability | 17,000 | 345,000 | 233,000 | — | — | |
| Liabilities assumed, net of non-cash assets received in Merger | 0 | 49,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro